澳大利亚母亲对婴儿呼吸道合胞病毒预防措施的偏好:离散选择实验
在澳大利亚2025年引入母体RSV疫苗和长效单克隆抗体两种预防措施前一年,研究通过在线焦点小组定性数据构建全国离散选择实验,调查1500名孕妇及有2岁以下儿童的母亲。结果显示母亲对单克隆抗体知晓率低、对疾病严重性认知不足,决策主要受费用、有效性和安全性影响;51.4%偏好母体疫苗,24.3%偏好单克隆抗体或不确定,全科医生为首选提供者。
要点
- 母亲对RSV疾病及单克隆抗体的知晓与认知水平低
- 费用、有效性、安全性是母亲决策的主要影响因素
- 51.4%偏好母体疫苗,全科医生为首选接种提供者
核心结论
- 在澳大利亚2025年2月引入婴儿混合RSV预防项目前,母亲对RSV疾病和预防措施的知晓率低。
- 母亲决策受费用、有效性和安全性担忧影响,需国家层面实施策略和统一资助项目以优化公平接种。
研究设计与样本
- 离散选择实验(DCE),由在线焦点小组定性数据构建全国调查问卷。
- 调查对象为1500名澳大利亚孕妇及有2岁以下儿童的母亲。
主要发现
- 对单克隆抗体的知晓和对疾病严重性的感知均较低。
- 51.4%的母亲偏好母体疫苗,24.3%偏好单克隆抗体或不确定。
- 全科医生(GP)是首选的预防措施提供者。
关键数值与推荐
- DCE属性包括有效性、费用、安全性、时机和疾病风险感知。
临床怎么用
- 开展RSV疾病及预防措施的健康教育以提升母亲知晓率。
- 在项目设计中重视费用、有效性和安全性以促进接种接受度。
- 发挥全科医生作为首选提供者的作用以推动实施。
局限性
- 定性数据仅来自有2岁以下儿童的澳大利亚母亲焦点小组,调查时间为项目引入前一年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Two RSV preventatives, a maternal RSV vaccine and a long-acting monoclonal antibody, were introduced in Australia in 2025. In the year prior to program introduction, we explored maternal acceptability, preferences, awareness and knowledge of disease and provider delivery preferences. DESIGN: Discrete Choice Experiment (DCE). SETTING: Qualitative data from online focus groups informed a national DCE survey. PARTICIPANTS: Qualitative data from Australian mothers with a child <2 years was collected through focus groups, identifying key themes for decision-making. The final attributes for the DCE survey included effectiveness, cost, safety, timing, and risk perception of the disease and was administered to 1500 pregnant people and mothers with a child <2 years. MAIN OUTCOME MEASURES: The primary outcomes were acceptability and maternal preferences for RSV preventatives and secondary outcomes were maternal awareness/knowledge of RSV and provider delivery preference. RESULTS: We found knowledge of the monoclonal antibody and perception of disease severity were low and maternal vaccine decision-making and acceptability of preventatives is strongly influenced by cost, effectiveness and safety. Overall, 51.4% of mothers preferred the maternal vaccine and 24.3% preferred the monoclonal antibody or were 'not sure' and general practitioners (GPs) were the preferred provider for delivery. CONCLUSION: Prior to the introduction of the hybrid RSV prevention program for infants in Australia in February 2025, we found that awareness of disease and RSV preventatives was low and that decision-making was influenced by cost, effectiveness and safety concerns. This study highlights the need for a national RSV implementation strategy and harmonised, Commonwealth-funded RSV program to optimise equitable uptake.
引用
- Danchin M, Rak A, Vasiliadis S, et al. Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment. Vaccine. 2026. PMID: 42134132. doi:10.1016/j.vaccine.2026.128710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。